Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 174; pp. S125 - S126
Main Authors Saggu, G., Stroopinsky, D., Dudek, A.Z., Olszanski, A.J., Juric, D., Dowlati, A., Vaishampayan, U., Assad, H., Rodón, J., Gibbs, J., Green, J., Du, Z., Rudicell, R., Kannan, K., Gharavi, R., Gomez-Pinillos, A., Fram, R.J., Berger, A., Sachsenmeier, K., Kasar, S.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2022
Online AccessGet full text

Cover

More Information
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(22)01134-0